The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...

Kewalramani cast the moment as an “opportunity to change the paradigm of acute pain management and establish a new standard of care.” Still, Journavx faces some hurdles in winning over ...

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...

The new FDA-approved pain drug is suzetrigine, with the brand name Journavx. Suzetrigine is designed to alleviate moderate to ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved in pain signaling.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...